Drugs Made In America Acquisition Corp. (DMAAR) Change in Accured Expenses (2025)
Drugs Made In America Acquisition's (DMAAR) quarterly Change in Accured Expenses came in at -$80439.0 in Q4 2025, down 151.84% quarter-over-quarter from $155170.0 in Q3 2025.
Powered by 
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) Change in Accured Expenses (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported Change in Accured Expenses for 1 consecutive years, with -$80439.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses changed N/A year-over-year to -$80439.0; the trailing twelve-month figure through Dec 2025 stood at $144904.0 (changed N/A YoY), and the FY2025 full-year result was $144904.0, up 87.51% from the prior year.
- Change in Accured Expenses fell to -$80439.0 in Q4 2025 per DMAAR's latest filing, from $155170.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $155170.0 in Q3 2025 and bottomed at -$80439.0 in Q4 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -80,439.00 |
| Sep 30, 2025 | 155,170.00 |
| Jun 30, 2025 | 14,970.00 |
| Mar 31, 2025 | 55,203.00 |